Cargando…

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia

Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment‐free remission (TFR). Many TFR studies to da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dulucq, Stéphanie, Mahon, Francois‐Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055167/ https://www.ncbi.nlm.nih.gov/pubmed/27367039 http://dx.doi.org/10.1002/cam4.801

Ejemplares similares

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Relevance of treatment‐free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2021)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2020)

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
por: Pavlovsky, Carolina, et al.
Publicado: (2021)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
por: Hughes, Amy, et al.
Publicado: (2017)

Long‐term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98‐LEDGF rearrangement
por: Gallego Hernanz, Maria Pilar, et al.
Publicado: (2019)

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
por: Kwaśnik, Paulina, et al.
Publicado: (2021)

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
por: Cross, N C P, et al.
Publicado: (2015)

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)): The phase 2, multicenter N‐Road study
por: Nishiwaki, Kaichi, et al.
Publicado: (2020)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
por: Malagola, Michele, et al.
Publicado: (2021)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
por: Caocci, Giovanni, et al.
Publicado: (2016)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
por: Lou, Jin, et al.
Publicado: (2018)

Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
por: Sharf, Giora, et al.
Publicado: (2020)

Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
por: Saifullah, Hilbeen Hisham, et al.
Publicado: (2021)

Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia
por: Fujioka, Yuki, et al.
Publicado: (2021)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
por: Yoshida, Chikashi, et al.
Publicado: (2023)

A genome‐scale CRISPR knock‐out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling
por: Lewis, Matthieu, et al.
Publicado: (2020)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
por: Ross, David M., et al.
Publicado: (2018)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
por: Rinaldi, Ikhwan, et al.
Publicado: (2023)

Planned Pregnancy in a Chronic Myeloid Leukemia Patient in Molecular Remission
por: Pavlovsky, Carolina, et al.
Publicado: (2012)

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
por: Sato, Eriko, et al.
Publicado: (2020)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon
por: Elias, Fadia, et al.
Publicado: (2019)

A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features
por: Liu, Fengqi, et al.
Publicado: (2019)

Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
por: Mu, Hui, et al.
Publicado: (2021)

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
por: Yamazaki, Kiyotaka, et al.
Publicado: (2020)

Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
por: Vigón, Lorena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l95v8154a4omvfrtekpjlbtmiq